[{"id":"09385123-8bb9-47ec-bcf2-5a9fd10802d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02435680","created_at":"2021-01-18T11:39:41.215Z","updated_at":"2024-07-02T16:36:28.871Z","phase":"Phase 2","brief_title":"Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT02435680","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • lacnotuzumab (MCS110)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/10/2015","start_date":" 08/10/2015","primary_txt":" Primary completion: 01/04/2020","primary_completion_date":" 01/04/2020","study_txt":" Completion: 03/23/2020","study_completion_date":" 03/23/2020","last_update_posted":"2021-06-21"},{"id":"ae04c4b0-5e58-41e5-a5a2-7672c264f891","acronym":"","url":"https://clinicaltrials.gov/study/NCT01643850","created_at":"2021-01-18T07:04:45.792Z","updated_at":"2024-07-02T16:36:36.582Z","phase":"Phase 2","brief_title":"MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)","source_id_and_acronym":"NCT01643850","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CSF1 • CD14","pipe":"","alterations":" ","tags":["CSF1 • CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lacnotuzumab (MCS110)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 04/23/2012","start_date":" 04/23/2012","primary_txt":" Primary completion: 12/07/2017","primary_completion_date":" 12/07/2017","study_txt":" Completion: 12/21/2018","study_completion_date":" 12/21/2018","last_update_posted":"2021-01-05"},{"id":"56ba012c-6b49-4c42-b104-3256ac5c372d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03285607","created_at":"2021-01-18T16:13:57.179Z","updated_at":"2025-02-25T15:53:51.201Z","phase":"Phase 1","brief_title":"MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer","source_id_and_acronym":"NCT03285607","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • lacnotuzumab (MCS110) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/30/2018","start_date":" 09/30/2018","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 02/28/2021","study_completion_date":" 02/28/2021","last_update_posted":"2018-08-16"}]